Business Wire

ADVA

8.6.2022 09:02:06 CEST | Business Wire | Press release

Share
Partner Communications utilizes ADVA synchronization solution for 5G timing

ADVA (FSE: ADV) today announced that Partner Communications has deployed its Oscilloquartz timing technology to support 5G rollout throughout Israel. The solution provides the level of accuracy and availability needed for next-generation mobile services and time-sensitive low-latency applications. Featuring ADVA’s Oscilloquartz core grandmaster devices, enhanced primary reference time clock (ePRTC) technology and multi-band GNSS receivers, the new timing infrastructure is ultra-resilient and prepared to withstand the rising threat of jamming and spoofing attacks. ADVA’s partner RDT Equipment & Systems also played a significant role in the deployment, carrying out installation, configuration and troubleshooting. Together with ADVA, it will provide Partner Communication with ongoing maintenance and support.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607006044/en/

“Upgrading a major nationwide mobile network like ours required the most advanced timing technology and the support of an expert team. That’s why we selected ADVA’s Oscilloquartz synchronization solution built on a core PTP grandmaster clock with full hardware redundancy and a scalable modular design. It offers many fan-out options, including PTP over multiple 10Gbit/s interfaces, and its advanced GNSS technologies ensure highest availability even under challenging conditions,” said Yigal Giladi, VP of engineering at Partner Communications. “With our new timing infrastructure, we can deliver the best possible mobile 5G experience to our customers. Now when GNSS is compromised or otherwise unavailable, ADVA’s ePRTC solution means we can still deliver phenomenally accurate timing across our network even during very long GNSS outages.”

Partner Communications’ new timing infrastructure features the OSA 5440 , a fully redundant, scalable, and modular multi-technology grandmaster for core deployment. Operating with the OSA 3230B ePRC cesium clock and OSA clock combiner, it provides an ePRTC system, providing high levels of time stability compliant with the ITU-T G.8272.1 standard. Onboard multi-band, multi-constellation receivers compensate for atmospheric disturbances to filter out timing errors. What’s more, centralized AI-powered GNSS assurance software identifies and protects against vulnerabilities of satellite-based timing. The solution also includes the OSA 5410 Series for continuous probing and assurance, enabling Partner Communications’ team to anticipate any issues and minimize disruption to service. The technology is remotely controlled by ADVA’s Ensemble Controller with Sync Director. This provides a powerful management platform, giving Partner Communications full visibility of its synchronization infrastructure and assuring accurate timing.

“Partner Communications has taken a major leap forward in terms of the accuracy and reliability of its synchronization network. Their team was determined to make their timing infrastructure the most precise and robust it could be, and so our engineers have worked tirelessly on design, testing and installation to ensure an end-to-end solution that delivers for Partner Communications’ customers now and for many years to come,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “This timing solution delivers a unique set of features to mitigate GNSS vulnerabilities, such as multi-band, multi-constellation receivers and AI-powered analytics. In a world of increasing jamming and spoofing attacks, this will prove invaluable for mobile users across Israel.”

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye